Erythropoietin Counteracts Breast Cancer Treatment with Herceptin
Researchers find erythropoiesis-stimulating drugs cut response to HER2 targeted therapy
MD Anderson News Release 11/15/10
Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from The University of Texas MD Anderson Cancer Center report in the Nov. 16 edition of Cancer Cell.
“Our research...
UT MD Anderson Pediatric Cancer Patients Ring in the Holidays with Artwork
New designs featured on Children's Art Project seasonal cards and gift items
MD Anderson News Release 11/11/10
With the holiday...
Holiday Exercise: No Gym Required
MD Anderson's Exercise Tips for the Holidays
MD Anderson News Release 11/12/2010
HOUSTON — By adding heart-pumping...
Texas Center for Cancer Nanomedicine Targets Two Tough Cancers
National Cancer Institute funds center of excellence to take on pancreatic, ovarian cancers
MD Anderson News Release 11/04/10
A $16-million, five-year grant by the National Cancer Institute's nanomedicine initiative blends the expertise of five research institutions to focus an array of innovative nanotechnologies on improving the outcome of patients with ovarian or pancreatic cancers.
The Texas Center for Cancer...
Armed Antibody Triggers Remissions for Hodgkin Lymphoma
Phase I trial establishes dose, catalogues side effects, hints at targeted drug's potential
MD Anderson News Release 11/03/10
<...